The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
FDA Approval: Blinatumomab
Abstract
On December 3, 2014, the FDA granted accelerated approval of blinatumomab (Blincyto; Amgen, Inc.) for treatment of Philadelphia chromosome–negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL). Blinatumomab is a recombinant murine protein that acts as a bispecific CD19-directed CD3 T-cell engager. The basis for the approval was a single-arm trial with 185 evaluable adults with R/R ALL. The complete remission (CR) rate was 32% [95% confidence interval (CI), 26%–40%], and the median duration of response was 6.7 months. A minimal residual disease response was achieved by 31% (95% CI, 25%–39%) of all patients. Cytokine release syndrome and neurologic events were serious toxicities that occurred. Other common (>20%) adverse reactions were pyrexia, headache, edema, febrile neutropenia, nausea, tremor, and rash. Neutropenia, thrombocytopenia, and elevated transaminases were the most common (>10%) laboratory abnormalities related to blinatumomab. A randomized trial is required in order to confirm clinical benefit. Clin Cancer Res; 21(18); 4035–9. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Gökbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.-A., Hüttmann, A., Kobbe, G., Kreuzer, K.-A., Leimer, L., Reichle, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399287 · Cited by 472
CHATENOUD, L., FERRAN, C., LEGENDRE, C., THOUARD, I., MERITE, S., REUTER, A., GEVAERT, Y., KREIS, H., FRANCHIMONT, P., & BACH, J.-F. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 320
Raetz, E. A., Borowitz, M. J., Devidas, M., Linda, S. B., Hunger, S. P., Winick, N. J., Camitta, B. M., Gaynon, P. S., & Carroll, W. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1414 · Cited by 222
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
O'Brien, S. M., Thomas, D. M., Ravandi, F., Faderl, S. H., Cortes, J. E., Borthakur, G., Pierce, S. A., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23919 · Cited by 150
Kantarjian, H. M., Thomas, D. A., Ravandi, F., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Pierce, S. A., Shan, J., Cortes, J. E., & O'Brien, S. M. (2010) · Cancer · doi:10.1002/cncr.25354 · Cited by 124
Zugmaier, G., Topp, M. S., Alekar, S., Viardot, A., Horst, H., Neumann, S., Stelljes, M., Bargou, R. C., Goebeler, M., Wessiepe, D., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.64 · Cited by 95
End points to establish the efficacy of new agents in the treatment of acute leukemia
Appelbaum, F. R., Rosenblum, D., Arceci, R. J., Carroll, W. L., Breitfeld, P. P., Forman, S. J., Larson, R. A., Lee, S. J., Murphy, S. B., O'Brien, S. M., et al. (2006) · Blood · doi:10.1182/blood-2006-08-041152 · Cited by 91
Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
Bloemena, E., ten Berge, I. J. M., Surachno, J. S., & Wilmink, J. M. (1990) · PubMed · Cited by 30
Cited by
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
Metadata
- Authors
- Przepiorka, D., Ko, C.-W., Deisseroth, A., Yancey, C. L., Candau-Chacon, R., Chiu, H.-J., Gehrke, B. J., Gomez-Broughton, C., Kane, R. C., Kirshner, S., Mehrotra, N., Ricks, T. K., Schmiel, D., Song, P., Zhao, P., Zhou, Q., Farrell, A. T., & Pazdur, R.
- Venue
- Clinical Cancer Research
- Published
- 2015-09-14
- Volume
- 21
- Issue
- 18
- Pages
- 4035-4039
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2220679566
- Cited by
- 373
- References
- 11
- FWCI
- 21.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval: Blinatumomab. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0612
- The paper
- Przepiorka, D., Ko, C.-W., Deisseroth, A., Yancey, C. L., Candau-Chacon, R., Chiu, H.-J., Gehrke, B. J., Gomez-Broughton, C., Kane, R. C., Kirshner, S., Mehrotra, N., Ricks, T. K., Schmiel, D., Song, P., Zhao, P., Zhou, Q., Farrell, A. T., & Pazdur, R. (2015). FDA Approval: Blinatumomab. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.